Up­dat­ed: Lon­za sets sights on ex­pan­sion, buy­ing No­var­tis fa­cil­i­ty; IQVIA leads $14 mil­lion Se­ries B fund­ing round

→ Lon­za Phar­ma & Biotech is ex­pand­ing, buy­ing up a Swiss fa­cil­i­ty No­var­tis has been us­ing to pro­duce drug vials and plug­ging it in­to their glob­al sup­ply net­work for in­dus­try clients. As is of­ten the case with these deals, Lon­za is pick­ing up the work for No­var­tis un­der con­tract. The fa­cil­i­ty has been up and run­ning for a decade now, serv­ing as the No­var­tis Cen­ter of Ex­cel­lence for ster­ile clin­i­cal (Phas­es I to III) drug prod­uct man­u­fac­tur­ing. Lon­za has al­ready an­nounced ex­pan­sions at its sites in Basel and Visp, Switzer­land and “from 2020 the group will ex­pand de­vel­op­ment and test­ing labs in­to a larg­er build­ing in Basel and ex­pects its Ibex So­lu­tions fill and fin­ish fa­cil­i­ty in Visp to be op­er­a­tional on-track from mid-2021.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER